ArticleAnnals of translational medicine2020
Association between genetic risk scores and risk of narcolepsy: a case-control study.
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 6 citations in OpenAlex.
- Association between human leukocyte antigen class II-DR-DQ and narcolepsy: a case control study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- Correlation analysis between HLA-DQA1*0102/DQB1*0602 genotypes and narcolepsy patients in China.Frontiers in neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGenome-wide association studies (GWASs) have identified a large number of single-nucleotide polymorphisms (SNPs) associated with narcolepsy. However, the sum impact of these SNPs on defining the genomic risk of narcolepsy remains unknown. In the present study, we investigated the associations between genetic risk scores (GRSs) and narcolepsy along with their predictive power.
methodsA case-control study consisting of 903 narcolepsy patients and 1,981 healthy control subjects was performed. Thirty-two SNPs previously reported to confer susceptibility to narcolepsy were assessed for their association with narcolepsy risk. Subsequently, we constructed four GRS groups comprising reported narcolepsy susceptibility SNPs located in different genomic regions, and tested their association with narcolepsy risk using a regression model. Receiver operating characteristic (ROC) curves were used to examine the discriminatory power of the GRSs for predicting narcolepsy.
resultsNine individual SNPs were significantly associated with narcolepsy after Bonferroni correction. All four GRSs were strongly associated with narcolepsy risk even when GRSs were constructed using SNPs located outside the previously implicated human leukocyte antigen (HLA) region on chromosome 6. The odds ratio (OR) for narcolepsy risk increased with the number of genetic loci implicated, ranging from an OR of 2.016 (95% CI, 1.657-2.456) to an OR of 4.298 (95% CI, 3.378-5.481). GRS4, constructed using the narcolepsy-associated SNPs identified in the Chinese population, was most closely associated with narcolepsy risk.
conclusionsThe results suggest that the GRS method for combining common genetic variations can significantly associate GRS scores with narcolepsy risk and may facilitate narcolepsy risk stratification for prevention trials, both for HLA-DQB1*06:02-positive and -negative individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.